Is tirzepatide linked to fewer deaths than GLP-1 drugs?
In 140,308 US adults with type 2 diabetes, tirzepatide was associated with lower all-cause mortality (AHR 0.58) and fewer major cardiovascular and kidney events than GLP-1 receptor agonists.
Source
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes
Study at a glance
- Design
- Cohort — Retrospective TriNetX cohort of US adults with type 2 diabetes initiating tirzepatide vs GLP-1 RA (June 2022–June 2023), with 1:1 propensity-score matching
- N
- N=140308 · 140,308 patients: 14,834 tirzepatide and 125,474 GLP-1 RA before matching; median follow-up 10.5 months
- Population
- US adults ≥18 years with type 2 diabetes starting tirzepatide or a GLP-1 RA, without baseline stage 5 CKD/kidney failure or recent MI/stroke
- Outcome
- All-cause mortality (primary); MACEs, kidney events, AKI, and major adverse kidney events
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Used TriNetX records of adults initiating tirzepatide or a GLP-1 RA, excluded advanced kidney failure and recent stroke/MI, matched on 48 variables, and compared mortality, MACEs, and kidney outcomes with Cox models.
What they found
After median 10.5 months, 0.6% vs 1.1% died on tirzepatide vs GLP-1 RA (AHR 0.58). MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) were also lower, with greater HbA1c and weight drops.
The limits
What it doesn't show
Observational matching cannot prove tirzepatide causes fewer deaths; residual confounding, short follow-up, and US EHR coverage limit causal and global claims.
Key terms
- Tirzepatide
- Dual GIP and GLP-1 receptor agonist used for type 2 diabetes and weight loss.
- GLP-1 RA
- Glucagon-like peptide 1 receptor agonist comparator class (e.g., semaglutide-type drugs).
- MACE
- Major adverse cardiovascular events: myocardial infarction, stroke, or cardiac death.
- MAKE
- Major adverse kidney event: stage 5 CKD, kidney failure/dialysis, or death.
- Propensity-score matching
- 1:1 matching on 48 demographic, comorbidity, medication, and lab variables.
- AHR
- Adjusted hazard ratio from Cox models after matching.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
Primary outcome was:
Common questions
How large was the cohort?
140,308 patients with type 2 diabetes (14,834 tirzepatide; 125,474 GLP-1 RA).
What was the primary outcome?
All-cause mortality (AHR 0.58; 95% CI 0.45–0.75).
How long was follow-up?
Median 10.5 months (IQR 5.2–15.7).
Were kidney outcomes better too?
Yes—kidney events AHR 0.52 and MAKEs AHR 0.54 vs GLP-1 RA.
More on Diabetes